Functionalanalysisofgeneexpressioninrisperidone treated cellsprovidenewinsightsinmolecular mechanism andnewcandidategenesfor pharmacogeneticstudies

European Neuropsychopharmacology

Volumn 23, Issue 4, 2013, Pages 329-337

  Mas, Sergi ^a,c,d   Gassó, Patricia ^a,c,d   Bernardo, Miquel ^a,b,c,d   Lafuente, Amalia ^a,c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Dopamine; Gene expression; Glutamate; Neurogenesis; Risperidone; Serotonin; Synaptic plasticity

Indexed keywords

DOPAMINE; GLUTAMIC ACID; RISPERIDONE; SEROTONIN;

ACTIN FILAMENT; ARTICLE; CARDIOVASCULAR DISEASE; CELL MATURATION; CELL POPULATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; METABOLIC DISORDER; MICROARRAY ANALYSIS; MORPHOGENESIS; MOTOR DYSFUNCTION; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER; NERVOUS SYSTEM DEVELOPMENT; NEUROBLASTOMA CELL; PHARMACOGENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYNAPSE VESICLE; DRUG EFFECT; GENE EXPRESSION REGULATION; METHODOLOGY; PHYSIOLOGY; TUMOR CELL LINE; DRUG EFFECTS; PROCEDURES;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; NEUROGENESIS; PHARMACOGENETICS; RISPERIDONE;

EID: 84881542384     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.04.016     Document Type: Article

References (39)

1. Al-Shahrour, F., Minguez, P., Tarraga, J., Medina, I., Alloza, E., Montaner, D., et al., 2007. FatiGO+: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments. Nucleic Acids Res. 35 ((Web Server issue), W91-6).
2. Chen, M.L., Chen, C.H., 2005. Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology 30, 268-277.
3. Chen, M.L., Chen, C.H., 2007. Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. J. Psychiatr. Res. 41, 57-62.
4. Choi, Y.K., Gardner, M.P., Tarazi, F.I., 2009. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur. Neuropsychopharmacol. 19, 77-84.
5. De Luca, V, Likhodi, O., Van Tol, H.H., Kennedy, J.L., Wong, A.H., 2006. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr. Scand. 114, 211-215.
6. Feher, L.Z., Kalman, J., Puskas, L.G., Gyulveszi, G., Kitajka, K., Penke, B., et al., 2005. Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem. Int. 47, 271-280.
7. Fijal, B.A., Kinon, B.J., Kapur, S., Stauffer, V.L., Conley, R.R., Jamal, H.H., et al., 2009. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J. 9, 311-318.
8. Fijal, B.A., Stauffer, V.L., Kinon, B.J., Conley, R.R., Hoffmann, V.P., Witte, M.M., et al., 2012. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J. Clin. Psychiatry 73, 367-371.
9. Gasso, P., Bernardo, M., Mas, S., Crescenti, A., Garcia, C, Parellada, E., et al., 2008. Association of A/G polymorphism in intron 13 of the monoamine oxidase B gene with schizophrenia in a Spanish population. Neuropsychobiology 58, 65-70.
10. Gasso, P., Mas, S., Bernardo, M., Alvarez, S., Parellada, E., Lafuente, A., 2009. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 9, 404-410.
11. Haddad, P.M., Sharma, S.G., 2007. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21, 911-936.
12. Honer, W.G., Young, C.E., 2004. Presynaptic proteins and schizophrenia. Int. Rev. Neurobiol. 59, 175-199.
13. Hyman, S.E., Nestler, E.J., 1996. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry 153, 151-162.
14. Iasevoli, F., Fiore, G., Cicale, M., Muscettola, G., de Bartolomeis, A., 2010. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Res. 177, 255-260.
15. Ikeda, M., Tomita, Y., Mouri, A., Koga, M., Okochi, T., Yoshimura, R., et al., 2010. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol. Psychiatry 67, 263-269.
16. Janssen, P.A., Niemegeers, C.J., Awouters, F., Schellekens, K.H., Megens, A.A., Meert, T.F., 1988. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244, 685-693.
17. Konradi, C., Heckers, S., 2001. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry 50, 729-742.
18. Lafuente, A., Bernardo, M., Mas, S., Crescenti, A., Aparici, M., Gasso, P., et al., 2008. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res. 161, 131-141.
19. Liou, Y.J., Bai, Y.M., Lin, E., Chen, J.Y., Chen, T.T., Hong, C.J., et al., 2010. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J.http://dx.doi.org/10.1038/tpj.2010.74.
20. Lit, L., Sharp, F.R., Bertoglio, K., Stamova, B., Ander, B.P., Sossong, A.D., et al., 2011. Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J.http://dx.doi.org/10.1038/tpj.2011.23.
21. Luca, V.D., Souza, R.P., Viggiano, E., Sickert, L., Teo, C., Zai, C., et al., 2011. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Hum. Psychopharmacol http://dx.doi.org/10.1002/hup.1219.
22. Medina, I., Carbonell, J., Pulido, L., Madeira, S.C., Goetz, S., Conesa, A., et al., 2010. Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res. 38 ((Web Server issue), W210-3).
23. Mittelstaedt, T., Schoch, S., 2007. Structure and evolution of RIMBP genes: identification of a novel family member. Gene 403, 70-79.
24. Moutsimilli, L., Farley, S., El Khoury, M.A., Chamot, C., Sibarita, J.B., Racine, V., 2008. Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways. Neuropharmacology 54, 497-508.
25. Müller, D.J., Klempan, T.A., De Luca, V., Sicard, T., Volavka, J., Czobor, P., et al., 2005. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci. Lett. 379, 81-89.
26. Musil, R., Spellmann, I., Riedel, M., Dehning, S., Douhet, A., Maino, K., et al., 2008. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J. Psychiatr. Res. 42, 963-970.
27. Newton, S.S., Duman, R.S., 2007. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21, 715-725.
28. Niculescu, A.B., 3rd Segal, D.S., Kuczenski, R., Barrett, T., Hauger, R.L., Kelsoe, J.R., 2000. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics 4, 83-91.
29. Niculescu, A.B., Le-Niculescu, H., 2010. Convergent functional genomics: what we have learned and can learn about genes, pathways, and mechanisms. Neuropsychopharmacology 35, 355-356.
30. Olincy, A., Harris, J.G., Johnson, L.L., Pender, V., Kongs, S., Allensworth, D., et al., 2006. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63, 630-638.
31. Pajonk, F.G., 2004. Risperidone in acute and long-term therapy of schizophrenia-a clinical profile. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 15-23.
32. Tanaka, S., Syu, A., Ishiguro, H., Inada, T., Horiuchi, Y., Ishikawa, M., et al., 2011. DPP6 as a candidate gene for neurolepticinduced tardive dyskinesia. Pharmacogenomics J.http://dx.doi.org/10.1038/tpj.2011.36.
33. Tarazi, F.I., Baldessarini, R.J., Kula, N.S., Zhang, K., 2003. Longterm effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 306, 1145-1151.
34. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman F., 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 (RESEARCH0034).
35. Vehof, J., Al Hadithy, A.F., Burger, H., Snieder, H., Risselada, A.J., Wilffert, B., et al., 2011. Association between the ROBO1 gene and body mass index in patients using antipsychotics. Psychiatr. Genet. 21, 202-207.
36. Verma, V., Lim, E.P., Han, S.P., Nagarajah, R., Dawe, G.S., 2007. Chronic high-dose haloperidol has qualitatively similar effects to risperidone and clozapine on immediate-early gene and tyrosine hydroxylase expression in the rat locus coeruleus but not medial prefrontal cortex. Neurosci. Res. 57, 17-28.
37. Wadenberg, M.L., Fjällström, A.K., Federley, M., Persson, P., Stenqvist, P., 2011. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor. Int. J. Neuropsychopharmacol. 14, 644-654.
38. Wang, X.D., Su, Y.A., Guo, C.M., Yang, Y., Si, T.M., 2008. Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int. J. Neuropsychopharmacol. 11, 553-561.
39. Zhang, J.P., Malhotra, A.K., 2011. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin. Drug Metab. Toxicol. 7, 9-37.